Charles P Chalekson, MD
Plastic and Reconstructive Surgery · Templeton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 30 years
- University of Southern California Keck School of Medicine, 1996
Offices
1 location · Charles Chalekson M D Inc · 2 clinicians in this group
Looking this up.
Hospitals listed: Marian Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chalekson’s office at (805) 434-2828 to ask if they take your plan before you enroll.
California Medical Board record
Licence A77782 · Current
Licensed to practise in California · since 2002 · expires 2027-10-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$23,492
Medicare paid this office $23,492 for 31 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 12 | $1,682 | $129 |
| Short return visit (20+ min) | 14 | $1,382 | $60 |
Procedures Medicare counted
| Mastectomy | 30 | More than 86% of doctors who do this |
| Melanoma (skin cancer) excision | 1-10 | None |
Who their Medicare patients are
31 Original Medicare patients in 2024. Average age 69 · 85 and older 0% · Health risk score 0.80. At or below the middle of the specialty; the typical plastic and reconstructive surgery clinician is at 1.21.
Conditions among them: Cancer 75% · High blood pressure 65%.
The office billed $388,281, Medicare allowed $30,333 and paid $23,492; for 106 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 31 | 106 | 69 | 0.80 | $388,281 | $23,492 |
| 2023 | 35 | 129 | 71 | 0.92 | $458,686 | $34,381 |
| 2022 | 37 | 136 | 71 | 0.90 | $488,920 | $32,176 |
| 2021 | 30 | 83 | 73 | 0.84 | $228,242 | $20,727 |
| 2020 | 34 | 105 | 73 | 0.95 | $274,950 | $25,747 |
| 2019 | 54 | 229 | 72 | 1.12 | $417,424 | $36,379 |
| 2018 | 63 | 211 | 69 | 0.88 | $378,894 | $44,390 |
| 2017 | 73 | 237 | 71 | 0.95 | $510,647 | $57,628 |
| 2016 | 59 | 203 | 74 | 1.17 | $255,932 | $38,378 |
| 2015 | 66 | 224 | 73 | 0.95 | $325,239 | $44,699 |
| 2014 | 77 | 269 | 70 | 1.01 | $510,567 | $71,796 |
| 2013 | 99 | 406 | 72 | 1.14 | $560,142 | $83,808 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Short return visit (20+ min) | 14 | $1,715 | $69 |
| Return visit (30+ min) | 11 | $1,264 | $90 |
2022: 1 service
| Short return visit (20+ min) | 16 | $1,623 | $68 |
2021: 1 service
| Short return visit (20+ min) | 15 | $1,064 | $67 |
2020: 2 services
| Return visit (30+ min) | 11 | $1,093 | $84 |
| Short return visit (20+ min) | 13 | $799 | $50 |
2019: 3 services
| Short return visit (20+ min) | 22 | $2,081 | $61 |
| Return visit (30+ min) | 12 | $1,164 | $78 |
| New patient visit (30+ min) | 12 | $1,065 | $89 |
2018: 4 services
| Short return visit (20+ min) | 29 | $1,867 | $47 |
| New patient visit (45+ min) | 14 | $1,771 | $127 |
| New patient visit (60+ min) | 12 | $1,479 | $123 |
| Return visit (30+ min) | 17 | $1,419 | $79 |
2017: 5 services
| New patient visit (60+ min) | 23 | $3,242 | $141 |
| New patient visit (45+ min) | 15 | $1,952 | $130 |
| Short return visit (20+ min) | 20 | $1,534 | $53 |
| Return visit (30+ min) | 17 | $1,242 | $69 |
| New patient visit (30+ min) | 12 | $973 | $81 |
2016: 5 services
| New patient visit (45+ min) | 21 | $2,308 | $110 |
| New patient visit (60+ min) | 12 | $1,979 | $165 |
| Short return visit (20+ min) | 18 | $1,293 | $56 |
| Long return visit (40+ min) | 11 | $1,257 | $114 |
| Return visit (30+ min) | 12 | $898 | $75 |
2015: 4 services
| New patient visit (45+ min) | 17 | $2,260 | $133 |
| Short return visit (20+ min) | 25 | $2,153 | $54 |
| New patient visit (30+ min) | 17 | $1,353 | $80 |
| Return visit (30+ min) | 11 | $1,040 | $80 |
2014: 5 services
| New patient visit (60+ min) | 20 | $3,175 | $159 |
| New patient visit (45+ min) | 23 | $2,718 | $118 |
| Return visit (30+ min) | 20 | $1,708 | $71 |
| Short return visit (20+ min) | 24 | $1,598 | $57 |
| Long return visit (40+ min) | 11 | $1,062 | $97 |
2013: 6 services
| Surgical change to reconstructed breast | 11 | $4,609 | $419 |
| Short return visit (20+ min) | 40 | $3,705 | $51 |
| Return visit (30+ min) | 36 | $3,318 | $81 |
| New patient visit (60+ min) | 16 | $2,579 | $161 |
| New patient visit (45+ min) | 20 | $2,267 | $113 |
| New patient visit (30+ min) | 23 | $1,591 | $69 |
Drugs they prescribed that Part D paid
$526
Pharmacies billed $526 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 32% of their Part D prescriptions (23 of 71) in 2024. Above the middle of the specialty; the typical plastic and reconstructive surgery clinician is at 28%. Surgeons prescribe little besides pain medicine after an operation, so their opioid share runs high.
70 generic and fewer than 11 brand-name prescriptions · $526 in drug cost · 23 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Scopolamine | 19 | $222 | $11 |
| Hydrocodone-Acetaminophen | 20 | $191 | $9 |
| Cephalexin | 16 | $60 | $3 |
Year by year
| 2024 | 71 | 29 | 32% (23) | None | $526 |
| 2023 | 99 | 44 | 34% (34) | None | $1,506 |
| 2022 | 83 | 35 | 40% (33) | 0% | $1,352 |
| 2021 | 44 | 20 | 36% (16) | 0% | $632 |
| 2020 | 49 | 22 | 43% (21) | None | $297 |
| 2019 | 51 | 31 | 61% (31) | 0% | $523 |
| 2018 | 58 | 24 | 41% (24) | None | $881 |
| 2017 | 45 | 21 | 44% (20) | None | $383 |
| 2016 | 39 | 25 | 54% (21) | None | $412 |
| 2015 | 41 | 17 | 37% (15) | None | $469 |
| 2014 | 62 | 31 | 50% (31) | None | $796 |
| 2013 | 56 | 22 | 41% (23) | None | $509 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Scopolamine | 27 | $433 | $16 |
| Hydrocodone-Acetaminophen | 32 | $318 | $10 |
| Cephalexin | 21 | $252 | $12 |
2022: 3 drugs
| Scopolamine | 22 | $515 | $23 |
| Hydrocodone-Acetaminophen | 32 | $284 | $9 |
| Cephalexin | 12 | $121 | $10 |
2021: 3 drugs
| Cephalexin | 11 | $320 | $29 |
| Scopolamine | 12 | $177 | $15 |
| Hydrocodone-Acetaminophen | 14 | $86 | $6 |
2020: 2 drugs
| Hydrocodone-Acetaminophen | 20 | $102 | $5 |
| Cephalexin | 14 | $78 | $6 |
2019: 1 drug
| Hydrocodone-Acetaminophen | 27 | $152 | $6 |
2018: 2 drugs
| Hydrocodone-Acetaminophen | 24 | $173 | $7 |
| Cephalexin | 12 | $66 | $5 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 18 | $95 | $5 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 16 | $162 | $10 |
2015: 2 drugs
| Hydrocodone-Acetaminophen | 11 | $110 | $10 |
| Sulfamethoxazole-Trimethoprim | 13 | $93 | $7 |
2014: 2 drugs
| Hydrocodone-Acetaminophen | 23 | $181 | $8 |
| Cephalexin | 18 | $113 | $6 |
2013: 2 drugs
| Hydrocodone-Acetaminophen | 17 | $140 | $8 |
| Cephalexin | 13 | $96 | $7 |
Money from drug and device companies
$3,666 in 2025
| 2025 | 4 | 13 | $1,928 | $3,666 |
| 2024 | 3 | 4 | None | $176 |
| 2023 | 2 | 3 | None | $51 |
| 2022 | 1 | 8 | None | $665 |
| 2021 | 2 | 5 | None | $595 |
| 2020 | 3 | 4 | None | $79 |
| 2019 | 4 | 8 | None | $4,278 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Motiva USA | Motiva Implant Matrix | $3,327 | 7 payments
|
| Revance Therapeutics | Daxxify | $278 | 4 payments
|
| Musculoskeletal Transplant Foundation | None | $31 | 1 payment
|
| Axogen | None | $30 | 1 payment
|
See all 13 published payments
| Musculoskeletal Transplant Foundation | Meals · 2025-11-19 | None | $31 |
| Axogen | Meals · 2025-07-30 | None | $30 |
| Motiva USA | Consulting · 2025-05-23 | Motiva Implant Matrix | $1,928 |
| Revance Therapeutics | Meals · 2025-05-19 | Daxxify | $67 |
| Motiva USA | Meals · 2025-04-25 | Motiva Implant Matrix | $325 |
| Motiva USA | Travel · 2025-04-25 | Motiva Implant Matrix | $25 |
| Motiva USA | Gift · 2025-04-25 | Motiva Implant Matrix | $87 |
| Motiva USA | Travel · 2025-04-24 | Motiva Implant Matrix | $785 |
| Motiva USA | Meals · 2025-04-24 | Motiva Implant Matrix | $163 |
| Revance Therapeutics | Meals · 2025-04-15 | Daxxify | $42 |
| Revance Therapeutics | Meals · 2025-04-02 | Daxxify | $104 |
| Revance Therapeutics | Meals · 2025-03-30 | Daxxify | $65 |
| Motiva USA | Meals · 2025-01-29 | Motiva Implant Matrix | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $176
| Revance Therapeutics | Daxxify | $68 | 1 payment
|
| Abbvie | Natrelle Saline-Filled Breast Implants | $55 | 1 payment
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $53 | 2 payments
|
2023: $51
| AbbVie | Natrelle Saline-Filled Breast Implants | $38 | 2 payments
|
| Musculoskeletal Transplant Foundation | None | $13 | 1 payment
|
2022: $665
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $665 | 8 payments
|
2021: $595
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $564 | 4 payments
|
| Mentor Worldwide | Artoura Breast Tissue Expander | $31 | 1 payment
|
2020: $79
| Allergan | Natrelle | $41 | 2 payments
|
| Apyx Medical | None | $23 | 1 payment
|
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $15 | 1 payment
|
2019: $4,278
| Allergan | Natrelle | $4,066 | 4 payments
|
| Biocomposites | Stimulan | $149 | 1 payment
|
| Mentor Worldwide | Memorygel Breast Implants | $43 | 2 payments
|
| TEI Biosciences | Surgimend | $20 | 1 payment
|
Professional record
- NPI
- 1770668642
- Licence
- CA A77782California A77782: Current · expires 2027-10-31
- Trained
- University of Southern California Keck School of Medicine, 1996 · 30 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A777820
- Taxonomy
- Federal specialty code 208200000X (208200000X); Federal specialty code 2082S0105X (2082S0105X)
- Mailing address
- 225 Posada Ln Ste 100, Templeton, CA, 93465
- NPI first listed
- 2006-10-26
- NPI last updated
- 2023-07-01
- NPI record certified
- 2023-07-01
This is when the NPI record was last certified, not a medical board exam.